Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;22(9):1495-1503.
doi: 10.1002/ejhf.1954. Epub 2020 Aug 5.

Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Petar M Seferović  1   2 , Gabriele Fragasso  3 , Mark Petrie  4 , Wilfried Mullens  5   6 , Roberto Ferrari  7 , Thomas Thum  8 , Johann Bauersachs  9 , Stefan D Anker  10   11 , Robin Ray  12 , Yuksel Çavuşoğlu  13 , Marija Polovina  1   14 , Marco Metra  15 , Giuseppe Ambrosio  16 , Krishna Prasad  17 , Jelena Seferović  1   18 , Pardeep S Jhund  19 , Giuseppe Dattilo  20 , Jelena Čelutkiene  21 , Massimo Piepoli  22 , Brenda Moura  23 , Ovidiu Chioncel  24   25 , Tuvia Ben Gal  26 , Stefan Heymans  27 , Rudolf A de Boer  28 , Tiny Jaarsma  29 , Loreena Hill  30 , Yuri Lopatin  31 , Alexander R Lyon  32 , Piotr Ponikowski  33 , Mitja Lainščak  34   35 , Ewa Jankowska  33 , Christian Mueller  36 , Francesco Cosentino  37 , Lars Lund  38 , Gerasimos S Filippatos  39 , Frank Ruschitzka  40 , Andrew J S Coats  41 , Giuseppe M C Rosano  42
Affiliations
Free article

Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

Petar M Seferović et al. Eur J Heart Fail. 2020 Sep.
Free article

Abstract

Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.

Keywords: Cardiovascular outcomes; Heart failure; Quality of life; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Koudstaal S, Pujades-Rodriguez M, Denaxas S, Gho J, Shah AD, Yu N, Patel RS, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail 2017;19:1119-1127.
    1. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-113.
    1. Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJ. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-872.
    1. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 2019;21:1306-1325.
    1. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA Heart Failure Long-Term Registry. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017;40:671-678.

Publication types